Sign Up Today and Learn More About Ashvattha Therapeutics Stock
Invest in or calculate the value of your shares in Ashvattha Therapeutics or other pre-IPO companies through EquityZen's platform.
Ashvattha Therapeutics Stock (ASHT)
Ashvattha Therapeutics is a biotechnology company that creates products that selectively target and treat human diseases.
About Ashvattha Therapeutics Stock
Founded
2015
Headquarters
Redwood City, CA, US
Industries
Science and Engineering, Health Care, Biotechnology
Ashvattha Therapeutics Press Mentions
Stay in the know about the latest news on Ashvattha Therapeutics
Ashvattha Therapeutics to Present at ARVO, Retina World Congress, and AOS Annual Meeting
globenewswire • Apr 15, 2025
Dendrimer compositions and methods for drug delivery to the eye
patents • Apr 02, 2025
Ashvattha Therapeutics Accelerates Clinical Development Strategy with Leadership Appointment of Six Leading Retinal Specialists to Clinical Advisory Board
biospace • Mar 19, 2025
Ashvattha Therapeutics Accelerates Clinical Development Strategy with Leadership Appointment of Six Leading Retinal Specialists to Clinical Advisory Board
globenewswire • Mar 18, 2025
Radiolabeled ether dendrimer conjugates for pet imaging and radiotherapy
patents • Feb 07, 2025
Ashvattha Therapeutics Management
Leadership team at Ashvattha Therapeutics
Board Director
Jay Zaveri
CBO
Matt Brewer
Join now and verify your accreditation status to gain access to:
- Ashvattha Therapeutics Current Valuation
- Ashvattha Therapeutics Stock Price
- Ashvattha Therapeutics Management
- Available deals in Ashvattha Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Ashvattha Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Ashvattha Therapeutics Revenue and Financials
- Ashvattha Therapeutics Highlights
- Ashvattha Therapeutics Business Model
- Ashvattha Therapeutics Risk Factors
- Ashvattha Therapeutics Research Report from SACRA Research
Trading Ashvattha Therapeutics Stock
How to invest in Ashvattha Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Ashvattha Therapeutics through EquityZen funds. These investments are made available by existing Ashvattha Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Ashvattha Therapeutics stock?
Shareholders can sell their Ashvattha Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
